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Background: Chronic traumatic encephalopathy (CTE) is a recently revived term used to describe a
neurodegenerative process that occurs as a long term complication of repetitive mild traumatic brain injury (TBI).
Corsellis provided one of the classic descriptions of CTE in boxers under the name “dementia pugilistica” (DP).
Much recent attention has been drawn to the apparent association of CTE with contact sports (football, soccer,
hockey) and with frequent battlefield exposure to blast waves generated by improvised explosive devices (IEDs).
Recently, a promising serum biomarker has been identified by measurement of serum levels of the neuronal
microtubule associated protein tau. New positron emission tomography (PET) ligands (e.g., [18 F] T807) that identify
brain tauopathy have been successfully deployed for the in vitro and in vivo detection of presumptive tauopathy in
the brains of subjects with clinically probable CTE.
Methods: Major academic and lay publications on DP/CTE were reviewed beginning with the 1928 paper
describing the initial use of the term CTE by Martland.
Results: The major current concepts in the neurological, psychiatric, neuropsychological, neuroimaging, and body
fluid biomarker science of DP/CTE have been summarized. Newer achievements, such as serum tau and [18 F] T807
tauopathy imaging, are also introduced and their significance has been explained.
Conclusion: Recent advances in the science of DP/CTE hold promise for elucidating a long sought accurate
determination of the true prevalence of CTE. This information holds potentially important public health implications
for estimating the risk of contact sports in inflicting permanent and/or progressive brain damage on children,
adolescents, and adults.Overview
Chronic traumatic encephalopathy (CTE) is unique among
brain diseases in having a history of decades of organized
opposition to its codification as an authentic or valid entity.
The conceptual entity has evolved over the 75 years since
Harrison Stanford Martland [1], writing in The Journal
of the American Medical Association in 1928, coined
the term “punch drunk” to describe the tremors and* Correspondence: samuel.gandy@mssm.edu
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unless otherwise stated.impaired cognition that affected some boxers [1]. In 1937,
Millspaugh [2] coined the term “dementia pugilistica” (DP),
which was broadened to “chronic traumatic encephalop-
athy” (CTE) by Macdonald Critchley [3] in 1949. In 1973,
John Corsellis and colleagues [4] brought DP/CTE
into the modern day with their definitive documentation
that progressive neurodegeneration (Figures 1 and 2) was
associated with elective exposure to repetitive head
trauma. This report set off a controversy that continues
today regarding the role of society in regulating inten-
tional head injury and in establishing the liability of
organizations that encourage such exposure with little
in the way of informed consent.
Despite condemnation of boxing by the American
Medical Association [6] and by the American PediatricsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Patterns of tau immunostaining in the frontal cortex of the patient with dementia pugilistica (DP), compared to Alzheimer’s
disease (AD) and nondemented cases. MC-1 immunolabeling of phosphorylated tau revealed neuronal labeling in the DP case (A),
plaque-associated neuritic labeling in the frontotemporal dementia (FTD)-AD case (B), a mix of neurofibrillary tangles (NFTs) and dystrophic neurites
in the typical AD case (C), but absent in the control case (D). AT8 immunoreactivity also was limited to intracellular NFTs in the DP case (E), and within
NFTs and plaque-associated dystrophic neurites in the FTD-AD case (F) and the typical AD case (G), but were not present in the control case
(H). PHF-1 immunostaining was the most extensive of the three pathological tau markers, and showed significant intracellular and extracellular NFT
labeling in the DP case (I), and within NFTs and plaque‐associated dystrophic neurites in the FTD-AD case (J), but was less extensive and
limited to NFTs in the typical AD case (K). No PHF‐1-positive tangles were observed in the control case (L; scale bar = 100 μm). From
Saing et al. [5] with permission.
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demise of boxing, the sport continues today, and multi-
million dollar purses still await the winners. In turn,
the chance to compete for these purses continues to
attract new boxers into professional associations, fueling
the sport. Other sports associated with repetitive head
trauma (e.g., ultimate fighting and mixed martial arts)
have expanded and found larger participant groups and
fans. Despite much social opposition to these sports, all
efforts at boxing bans have so far been stymied by the
influence of pro-boxing lobbyists on state and federal
legislatures [8]. While over 50 sports-associated cases of
CTE have been reported [9], efforts at educating the
public regarding the risks of repetitive head injury are
hindered by some retired boxing champions who refuse
to recognize that their own brain disease is due to their
chronic exposure to boxing. Newer “sports” involving
various forms of fighting provide further encouragement.
In 2005, Omalu and colleagues [10] revived the term
CTE in their report of the index case of a retiredNational Football (NFL) player with progressive neuro-
logical dysfunction (Figure 3). The term CTE includes
DP and supplants the use of the term DP. With the
increasingly evident association of CTE with American
football, the stakes grew exponentially. In part as a result
of the NFL’s consistent denial of the danger of CTE to
its players, in both public statements and legal challenge
statements, the disease remained out of the spotlight
until the League aligned itself with the independent and
academic experts who were studying the disease [11].
CTE has also been associated with other high impact
sports (soccer, hockey) and with exposure to improvised
explosive devices (IEDs) in the battlefields of Iraq and
Afghanistan [12-14] (Figure 4). Now, in the 21st century,
the challenge is no longer the acceptance of the entity of
CTE but rather a sorely needed accounting of the actual
numbers of affected persons as well as the numbers of
those who remain unaffected despite exposure to the
identical repetitive head traumas. The role of aging has
also gone unexplored. With those numbers in hand, we
Figure 2 Frontal cortical beta-amyloid (Aβ) neuropathology in dementia pugilistica (DP) as compared to that of Alzheimer’s disease
(AD) and nondemented control cases. Aβ1-16 immunostaining illustrates primarily diffuse plaque and extracellular neurofibrillary tangle (NFT)
labeling in the DP case (A) as compared to the extensive plaque labeling seen in the frontotemporal dementia (FTD)-AD case (B), and the typical
AD case (C), but is absent in the control case (D). Aβ1-42 immunostaining in the DP case (E), the FTD-AD case (F), the typical AD case (G), and
the control (H), was similar to that observed with immunolabeling for Aβ1-16. Less Aβ1-40 immunolabeling was observed in the DP case (I), with
deposits being primarily seen within diffuse plaques and on extracellular NFTs. In comparison, Aβ1-40 was observed in plaques in the FTD-AD
case (J), and primarily within neuritic plaque cores and associated with blood vessels in the typical AD case (K), and was absent in the control
case (L; scale bar = 500 μm). From Saing et al. [5] with permission.
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estimate of the true risk of each sport or type of military
activity taken with consideration of the actual or estimated
number of TBI episodes, without or with loss of conscious-
ness. Accurate epidemiology, in turn, would facilitate the
identification of risk factors for adverse cognitive outcomes,
including the role of genetics in susceptibility.
Other key issues surrounding CTE diagnosis and
research have emerged. While the boxers with DP were
usually apathetic in disposition, those with sports and
military TBI show prominent emotional dysregulation and
sometimes violence, especially suicide [16]. This behavioral
difference, while not yet completely analyzed, raises the
question of whether abuse of steroids or other licit or illicit
drugs might play roles in CTE [17]. This emotional dysreg-
ulation can include depression, anxiety, agitation, aggres-
sion, and a post-traumatic stress disorder-like (PTSD-like)
clinical phenotype [18]. Since these are symptoms more
likely to lead to psychiatric referral, a complete accounting
of clinical CTE will require an alliance between neurologists
(who frequently receive the dementia referrals especially inpatients under 60 yrs of age), psychiatrists (who frequently
receive the neuropsychiatric referrals), and neuropatholo-
gists (whose opinions are currently required to distinguish
CTE from Alzheimer’s disease [AD] and other pathological
entities). Neuroradiologists will play increasingly important
roles as magnetic resonance imaging (MRI) methodologies
and other neuroimaging biomarkers (i.e., amyloid imaging,
tauopathy imaging; Figure 5) mature and are validated.
On the occasion of the first promising blood biomarker
for TBI that correlates with outcome and the presentation
of the first tauopathy PET images that support a diagnosis
of CTE during life, we take this opportunity to review the
existing knowledge about CTE up to now.
Neuropsychology of CTE
The recommended assessment in CTE includes neuro-
psychological evaluation, neurological examination, brain
imaging, and blood and CSF biomarkers. Particular atten-
tion should be paid to cognitive function, mood, per-
sonality, behavior, and olfaction [20]. Most of what is
known about neuropsychological function in CTE comes
Figure 4 The index case of military CTE. Photomicrographs of tau-immunostained section of the frontal cortex showing frequent neurofibrillary
tangles and neuritic threads (A and B), with higher magnification (C and D) showing band- and flame-shaped neurofibrillary tangles and neuropil
neuritic threads. Original magnification × 200 (A), × 400 (B), × 600 (C and D). From Omalu et al. [15] with permission.
Figure 3 Micrographs from the index case of CTE in an American football player. Panel A, β‐amyloid immunostain of the neocortex (original
magnification, ×200) showing frequent diffuse amyloid plaques. Panel B, tau immunostain of the neocortex (original magnification, ×200) showing
sparse NFTs and many tau-positive neuritic threads. Panel C, tau immunostain (original magnification, ×400) showing an NFT in a neocortical neuron
with extending tau-positive dendritic processes. Panel D, β-amyloid immunostain (original magnification, ×100) of the Sommer’s sector (CA-1 region of
the hippocampus) showing no diffuse amyloid plaques. From Omalu et al. [10] with permission.
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Figure 5 [18 F] T807 autoradiography on brain sections and its comparison with paired helical filament (PHF)-tau and amyloid beta
(Aβ) double immunohistochemistry (IHC). (A) Representative images for [18 F] T807 autoradiographs from groups A, B, and C of brains ([18 F]
T807 autoradiography, 20 μCi/section). Positive autoradiography signals were observed only in the gray matter of brain from the PHF tau rich
group A. Arrows indicate gray matter. (B) [18 F] T807 colocalized with PHF-tau but not with Aβ plaques. (B, top row) Low magnification.
(B, bottom row) High magnification from the framed areas. Images of PHF tau (left) and Aβ (right) IHC double immunostaining and autoradiogram
image (middle) from two adjacent sections (10 μm) from a PHF-tau rich group A brain (frontal lobe). Positive [18 F] T807 labeling colocalized with
immunostaining of PHF tau but not with Aβ plaques, as indicated by arrows. Fluorescent and autoradiographic images were obtained using a Fuji Film
FLA-7000 imaging instrument. Scale bars = 2 mm. From Xia et al. [19] with permission.
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players, athletes from other contact sports, as well as
those exposed to domestic violence, and military personnel
exposed to battlefield blast injuries [20,21]. However, there
have been no prospective studies linking clinical pheno-
types during life (including neuropsychological function
and outcome) with autopsy-confirmed CTE. Thus, the
clinical and neuropsychological characterization of CTE
is yet to be properly developed. The development of
biomarkers for CTE (reviewed in detail below) should
greatly facilitate the fulfillment of this goal.
In their review of 48 cases of neuropathologically
confirmed CTE, McKee et al. [21] found that memory
loss was reported in over half of the individuals. As in AD,
loss of insight often precluded patients from recognizing
their deficits, and this important piece of the presentation
was derived from friends or family. Other studies have
reported that impairment in executive function is commonin neuropathologically confirmed CTE [22]. Executive func-
tions are a collective set of higher order abilities (judgment,
self-inhibitory behaviors, decision-making, planning and
organization) considered to be primarily dependent upon
adequate functioning of the frontal lobes of the brain.
Damage to various regions of the frontal cortex can disrupt
these higher order abilities, leading to poor impulse control,
and socially inappropriate, avolitional, and apathetic behav-
iors. For example, damage to the orbitofrontal regions can
result in significant changes in personality. Thus, changes
in personality, apathy, impulsivity, aggression, and “short
fuse” behaviors typical of CTE [23] are consistent with the
atrophy and other neuropathological changes of the frontal
lobes that have been described in nearly all reported cases
of CTE [16,21-24].
Neuropsychological, mood, and neurobehavioral dysfunc-
tion in CTE typically presents in midlife after a latency
period, usually years or decades after exposure to the
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of CTE begin insidiously, followed by progressive and
gradual deterioration. Mood symptoms are typically depres-
sion, apathy, irritability, and suicidality. Behavior symptoms
are impulse control, disinhibition, and aggression as
well as comorbid substance abuse [24]. The continued
degeneration of brain regions most severely affected in
CTE (cerebral cortices, hippocampi, amygdalae, basal
forebrain, mammillary bodies) results in the worsening of
behavioral and mood symptoms, and the further deterior-
ation of cognitive abilities subserved by these regions.
Baugh et al. [24] organized the neuropsychological and
neuropsychiatric symptoms of CTE into the categories of
cognition, mood, and behavior. As mentioned, the early
cognitive symptoms of CTE involve memory impairment
and executive dysfunction. The early involvement of
hippocampal-entorhinal cortices and medial thalamic
circuits may explain the memory impairment and its
similarity to the memory loss associated with AD. As in
AD, the genetic risk posed by apolipoprotein E ε4
(APOE ε4) may play a role in the dementia associated
with CTE [25-27]. The dysexecutive syndrome in CTE
may result from the early neurofibrillary degeneration
of the frontal cortex [10,21,22]. As the disease progresses,
there is worsening memory impairment and executive
dysfunction, language problems, motor dysfunction, ag-
gression (physical as well as verbal), and apathy [23].
Dementia is evident in most CTE individuals who live
to be over the age of 65 years [24]. However, the high
rates of suicides, accidents, and drug overdoses often
lead to death prior to this age [10,28]. As a result, most
persons with neuropathologically confirmed CTE were
not demented at the time of death. In view of the young
age of onset as compared with AD, CTE may be misdiag-
nosed as the behavioral variant of FTD. However, CTE
has a more gradual and prolonged progression than does
FTD, and CTE is associated with a repetitive TBI history
but with no family history [24].
Neuropsychological testing may be valuable in scientific
studies on TBI in both the acute and chronic phases.
Athletes and military combatants exposed to multiple
blast events are at highest risk for sustaining multiple
mild TBI or concussions and potentially developing CTE.
In order to appreciate fully the effects of single and
multiple concussive and sub-concussive brain injuries
and to enable tracking of recovery in individual cases,
brief baseline and serial post-concussion neurocognitive
assessments, based upon the Sports as a Laboratory Assess-
ment Model (SLAM) methodology, are the recommended
standard of practice [29]. Key neurocognitive elements of
these abbreviated assessments include attention, processing
speed, reaction time, and learning and memory.
Once CTE is suspected, based upon a history of repeated
trauma and presence of cognitive and/or behavioral impair-ment, scientific studies are needed to evaluate the value of
comprehensive neuropsychological testing; e.g., assessment
of general verbal and visuospatial problem solving, language
fluency, attention, learning and memory, speed of mental
processing, abstract reasoning, judgment, new problem
solving, planning and organization, mental flexibility, sen-
sory and motor intactness, and emotional/psychological
and behavioral functioning. A recent cross-sectional study
assessed cognitive impairment and depression, as well as
the neuroimaging correlates of these dysfunctions, in former
NFL players [30]. Former NFL players with cognitive impair-
ment and depression were compared to cognitively normal
retired players who were not depressed, and a group of
matched, healthy control subjects. The cognitive deficits
found were primarily in naming, word-finding, and memory
(verbal and visual) and were associated with disrupted white
matter integrity on DTI and changes in regional cerebral
blood flow. Although none of the players fit the clinical profile
of CTE per se, the sample size was very small. Nevertheless,
this is one of the first studies examining the neural correlates
of cognitive dysfunction and depression in players with a his-
tory of concussions (range 1–13 concussions in this sample).
Neuropathological changes in boxers (dementia pugilistica,
punch-drunk syndrome)
For this section, the combined term DP/CTE is employed,
since the term DP appears in this original literature. How-
ever, the revival of the term CTE was intended to include
DP and to supplant the use of the term DP. In 1934,
Parker described three cases of boxers affected with the
illness [31] and drew attention to the risk of developing
DP/CTE in professional boxing. Neuropathological exam-
ination of these retired professional boxers’ brains dem-
onstrated that the primary DP/CTE lesion involved
multifocal intracellular aggregates of hyperphosphorylated
tau, which resembled the neurofibrillary tangles (NFT)
found in AD brains [32]. Using Congo red and silver stain-
ing, Corsellis and colleagues studied 15 cases of DP/CTE
and confirmed the abundance of NFT. Like the NFT of
AD, the NFT of DP/CTE is also reactive to antibodies to
other AD-related proteins such as ubiquitin [33] and Aβ
[34]. The anatomical patterns of NFT distribution are
different in DP/CTE and AD: there is greater involvement
of superficial layers of the associational neocortex in cases
with DP/CTE and notably in the depths of cortical sulci
[35]. This difference may reflect a unique way in which
NFT are formed and propagated in DP/CTE.
In clear distinction to neuropathologically confirmed
AD, no congophilic or argyrophilic plaques were observed
in the Corsellis study [32]. In 1991, other investigators
re-examined 14 out of the original 15 DP/CTE cases
from the Corsellis study as well as additional brains of
professional and amateur boxers, using Aβ immunohis-
tochemistry and formic acid pre-treatment of tissue
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brains with NFT pathology (and even two amateur fighters’
brains that lacked NFT) also had Aβ-immunoreactive pla-
ques [34,36-38]. These DP/CTE plaques were described as
diffuse in most cases; they lacked both Congo red positivity
and the silver-positive dystrophic neurites that are typ-
ical of mature AD plaques. Some cases also displayed
cerebrovascular deposits of Aβ. These data demonstrated
that DP/CTE is associated with both the NFT and Aβ-
related AD-like pathology. The antigenic similarities of
neurofibrillary lesions in DP and AD led Roberts to suggest
that the two conditions likely share the same pathogenesis
and that TBI may be a risk factor for developing AD [37].
More recent studies reconfirmed that DP/CTE includes
both NFT and Aβ pathology. Tokuda et al. [38] and Nowak
et al. [39] examined the brains of boxers who suffered a
progressive cognitive decline before death, and reported
NFT as well as infrequent neuritic Aβ plaques. McKee
and colleagues [21] studied two aged (80 and 73 years)
professional boxers and presented them along with 37
previously published cases of boxers with neuropatho-
logically verified DP/CTE. Similar to earlier reports, the
most striking pathological feature in these two cases
involved multifocal patches of neuronal and astrocytic
NFT in superficial cortical layers, most frequently at
the depths of the sulci and around large blood vessels
[21]. In one of the two boxers, there were moderate
diffuse Aβ plaques and sparse neuritic plaques in several
neocortical regions. Collectively, these reports indicate
that the neuropathology of DP/CTE was heterogeneous
and involves both NFT and diffuse Aβ deposits, although
the extent and proportions of these lesions vary from case
to case and may be influenced by other factors such as
number of years since TBI, age at the time of the TBI,
and genetic predisposition. In a study by Geddes and
colleagues, the brain of a 23-year-old boxer was found to
have all neocortical areas affected with NFT; however no
other changes (including Aβ deposits) were reported [40].
APOE ε4 alleles have been associated with more severe
cognitive deficits in boxers [25] and could contribute to
more severe Aβ pathology, as has been demonstrated in
AD. In an APOE ε4 heterozygous retired boxer with DP/
CTE, death was caused by hemorrhage due to amyloid
angiopathy [41]. Clinical misdiagnosis of DP/CTE as AD
is not unusual; interestingly, both boxers in the McKee
report were diagnosed with AD during life. Differential
diagnosis is likely to be clarified with amyloid imaging. We
reported a case report illustrating this wherein the clinical
diagnosis of retired NFL player could not be resolved until
florbetapir imaging excluded the diagnosis of AD [42].
Other common findings in DP/CTE include cerebral
infarcts and fenestrated cavum septum pellucidum (CSP)
as well as substantia nigra degeneration [28]. Changes in
substantia nigra could explain the increased incidence ofParkinsonism in retired boxers. It had been proposed that
identification of CSP on CT scans could be of a diagnostic
value for DP/CTE [43]. However this pathological feature
is not consistently present [44], possibly because of the
high prevalence of CSP in both boxers and non-boxers
[45]. Because of the rigid enclosure of the brain inside
the calvarium, acceleration-deceleration injuries associated
with boxing often involve cerebral and meningeal vascular
damage, the most common of which is subdural hematoma
and to a lesser extent epidural, subarachnoid, and/or intra-
parenchymal hemorrhages [46]. Neuropathological sequelae
of boxing appear to be less severe in amateur boxers, likely
due to better-implemented regulations, fewer total bouts,
and other measures of protection. In retired professional
boxers, however, the risk of developing DP/CTE is greater:
the extent of neurological abnormalities defined by CT and
EEG, and severity of DP/CTE symptoms, correlated with
numbers of fights and overall duration of boxers’ career
[25,47,48].
Not shown here are some other CTE-associated struc-
tures described by McKee [21] including astrocytic tangles,
perivascular tau pathology, or patchy tau pathology. An im-
portant significance for these structures is that McKee uses
their presence to differentiate CTE from AD. The reader is
referred to [21] for typical images of those structures.
Neuropathological changes associated with American
football
In contrast to the neurodegenerative changes associated
with professional boxing, the chronic neuropathological
sequelae of repetitive hits to the head in American football
and other contact sports (hockey, rugby, etc.) have only
been recognized more recently. Impacts to the head in
American football cause less rotational acceleration than
those suffered in boxing [49]; football-related injuries are
of a translational acceleration-deceleration type, and des-
pite the use of helmets, they can result in concussions or
unconsciousness. In 2005, Omalu and colleagues reported
the first neuropathology finding of CTE in a 50-year old
retired NFL player [10]. In this case, they described AD-like
changes that consisted of neocortical Aβ-immunoreactive
plaques and sparse tau-immunoreactive neuronal and
axonal aggregates resembling NFT and neuropil threads.
While coexistence of Aβ plaques and NFT might have
suggested an ongoing AD process, several observations
argued against this idea: 1) there was no family history
of AD; 2) at autopsy, the brain had no signs of cortical
atrophy or overt neuronal loss; 3) the neocortical Aβ-
immunoreactive plaques were numerous, but were diffuse
(non-neuritic); and 4) NFT were scarce in the neocortex
and absent in the entorhinal cortex and hippocampus
which is the initial focus of NFT development in AD, prior
to any cortical NFT [50]. The neuropathological pattern
consisting of diffuse neocortical Aβ plaques and scarce
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acute severe TBI [51] or in cases with preclinical AD,
suggesting that both mild repetitive and severe brain
injuries may initiate early AD-like changes. The second
case reported by Omalu and colleagues [52] was a 45-year
old retired NFL player who had numerous cortical
and subcortical tau-immunoreactive NFT and neuropil
threads, but no Aβ-immunoreactive plaques. In a more
recent study, McKee and colleagues [21] described CTE
in a 45-year old retired football player and compared their
findings to previous neuropathology reports in four
players who had played similar positions during their
career. Tau-immunoreactive NFT-like neuronal and glial
(fibrillar astrocytic) profiles and thread-like neuropil neur-
ites were frequent in multiple cortical regions, predomin-
antly occupying deep sulcal and perivascular locations
[21]. NFT were also abundant in the entorhinal cortex,
hippocampus, amygdala, nucleus basalis and septal nuclei,
hypothalamus, thalamus, striatum, and olfactory bulb.
Diffuse Aβ plaques were reported in 3 of the 5 cases [21].
As in CTE due to boxing (i.e., DP), there are similarities of
the effects of football injuries to AD and other neurode-
generative disorders, notably involving NFT and diffuse Aβ
deposition, and these findings require further investigation.
Neuropathological changes associated with battlefield
blast exposure
Studies of military servicemen who participated in recent
wars indicate that repetitive mild head injury and concus-
sions due to blast (explosive) injury might also result in
CTE. This literature is the least mature since the index
case of military CTE was only reported by Omalu a few
years ago [15]. Brody and colleagues used diffusion tensor
imaging (DTI) to evaluate the extent of axonal injury in
63 U.S. military personnel diagnosed with mild TBI after
blast exposure with secondary mechanical injuries [53].
They found that, in these subjects, TBI was associated
with significant axonal injury, which was still present
6–12 months later at follow up evaluation with DTI.
Diffuse loss of white matter integrity was also detected
using high angular resolution diffusion imaging (HARDI)
in military veterans from Iraq and Afghanistan who had
been diagnosed with mild TBI and comorbid PTSD [54].
Collectively, these findings indicate that TBI associated
with blast or chronic mild injury produces chronic neur-
onal damage. Blast injuries and closed head injuries
have similar clinical features [55], however, the extent of
neurological damage in blast injured veterans is likely
influenced by injuries of other systems, since air-filled
organs (including lungs) are often severely affected [56,57].
Goldstein [58] and colleagues performed postmortem
analyses of brain tissues from four military veterans who
were exposed to blast or concussive injury and compared
them to four professional athletes who suffered repetitiveconcussions. In the neocortex from military veterans,
there were frequent perivascular and deep sulcal accumu-
lations of NFT-like tau-positive neurons and glial cells as
well as dystrophic axons were reported [58]. Subcortical
white matter in close proximity to these lesions had dys-
trophic axonal changes and clusters of activated microglia
were described. These pathological changes were similar
to those observed in sports CTE. The findings in this study
have been challenged because all military CTE subjects
had histories of both civilian and military TBI, making it
impossible to distinguish which lesions arose from which
injuries. Similar tau-immunoreactive neuropathological
features were described in an Iraqi war veteran with PTSD
who had been exposed to multiple blast explosions during
his deployments [15]. These autopsy studies of brains
from blast-injured veterans are not in agreement with
recent body fluid biomarker analyses in soldiers exposed
to blast [53], emphasizing both the variability of such
injuries and the variability in the accuracy of the historical
details surrounding the injuries. In this study of Army
officers exposed to different levels of blast overpressure
by firing heavy weapons, Blennow and colleagues [59]
measured CSF biomarkers of neuronal injury (tau and
neurofilament protein) or glial injury (GFAP and S-100β)
as well as CSF/serum albumin ratio, hemoglobin, and
bilirubin content in CSF. GFAP and S-100β were also
analyzed in serum samples. All analyses indicated normal
levels of examined markers, leading the authors to conclude
that high-impact blast was not associated with biomarker
evidence of brain damage [59]. The discrepancy between
this report and published evidence of neuropathology in
blast injured servicemen warrants further investigation, and
the issue of whether the blast wave itself causes injury remains
open. Another possible explanation is the lag time between
injury and serum sampling. Both [53] and [59] illustrate the
discrepancy between neuropathology that can be static and
long-lasting vs serum biomarkers that will rise acutely and
then fall as the marker molecule is cleared. Recent studies
of serum tau as a marker of acute TBI in hockey players
showed surprisingly good correlation with outcome [60].
Molecular pathogenesis of CTE
As noted above, CTE is considered to be primarily a
tauopathy with frequent coexistence of Aβ pathology.
Notably acute severe TBI is associated with diffuse Aβ
plaques and minimal tau pathology [51]. Other types of
abnormal protein aggregates are less common in CTE;
for example, alpha-synuclein immunoreactive inclusions
were not reported in any of 51 CTE cases reported by
McKee and colleagues [21]; however, they were detected
only following acute severe TBI [51]. Multiple cases of
Parkinsonism have been reported in professional boxers,
and there is increased prevalence of ALS in professional
football [61] and soccer players [62].
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As observed in cases with single severe head trauma, axonal
injury occurs in CTE, and this may be responsible for
accumulation of phosphorylated tau. Tau is a microtubule-
associate protein which can undergo excessive phosphoryl-
ation in the pathological milieu of brain injury associated
with ischemic foci that increase the risk of damage from
oxidative stress. The idea of ischemic changes as a contrib-
uting factor to tau hyperphosphorylation and formation of
NFT-like changes in CTE is consistent with their preferen-
tial deep sulcal and perivascular localization. Because both
neuronal and astrocytic NFT are observed in these areas, it
is possible that changes in tau are related to a more general
injury response mechanism that is not injury-specific or
cell-specific (e.g., brain ischemia, inflammatory reaction).
Diffuse axonal injury (DAI) is the most consistently
reported neuropathological feature following acute head
trauma [63]. DAI is associated with intra-axonal accu-
mulation of tau, Aβ-precursor protein (APP), ubiquitin,
and α-synuclein [64,65]. As an acute reaction to TBI,
there is an upregulation of APP and/or a switch in its
metabolic processing resulting in increased concentra-
tions of Aβ, which can deposit in diffuse, predominantly
Aβ42, plaques both acutely after severe TBI [51] and
chronically in boxers with DP/CTE. In studies of both
autopsy cases and in surgical biopsy tissue from subjects
with TBI [51], about 30% of acute severe TBI patients
are reported to show evidence of Aβ plaques. Aβ deposits
in CTE have received less attention in the literature than
has the tauopathy; however these changes may have a
significant role. The development of Aβ lesions may
depend on age of the subject, time interval since the head
injury, and genetic factors. More extensive and mature Aβ
pathology (i.e., neuritic plaques) may be absent, or may
recede over years, in subjects with protective genetic
factors that can result in better degradation/clearance of
Aβ from the brain [66,67], while tau-related pathology
may develop more slowly, may be more resistant to
degradation and therefore observed at late stages of
disease. Other genetic factors (APOE4) may influence
Aβ pathology. The link of APOE ε4 to dementia in CTE
is unexpected on the basis of tauopathy, since APOE ε4
modulates Aβ pathology in AD but not tauopathy. Perhaps
APOE ε4 modulates the severity of the acute Aβ deposition
which, in turn, affects clinical severity. This is a key
point in determining which types of interventions will
be most promising and at what point in pathogenesis
each is most likely to be successful. Recent evidence that
chronic action of interleukin-1β can reduce amyloidosis
while exacerbating tauopathy raises the possibility that
this neurodegeneration-associated cytokine may drive
the conversion of acute post-traumatic Aβ deposition
to chronic tauopathy with only minimal or inconsistent
Aβ residua [68].Alternatively, the extent and type of neuropathology
changes in CTE resulting from different contact sports
may reflect differences in the biomechanics associated
with head injury, including impact level (force) and type
of head movement (rotation, acceleration, deceleration).
Novel genetic, biomarker, and neuroimaging analyses
should be developed and employed for early detection of
neuropathology, to provide a window of opportunity for
preventing or at least delaying the clinical manifestations
of neurodegenerative disease after TBI. Furthermore,
timely identification of people at risk (e.g., APOE ε4
carriers) [27], and regular testing (imaging, CSF analyses,
and detailed neuropsychological evaluation) should be
considered essential.
Modeling CTE in laboratory animals
Currently there is no experimental animal model that
recapitulates all pathophysiological aspects of human CTE.
The best understood pathophysiological mechanisms
associated acutely with severe blunt impact TBI are
hemorrhage, mechanical tissue damage, and diffuse axonal
injury (DAI) [69]. DAI results when angular forces cause
shearing or stretching of axons; this can impair axonal
transport which is manifested pathologically by focal
axonal swellings, most commonly at gray/white matter
junctions particularly in frontal and temporal cortical
regions. Contusions occur as the result of coup/contre-
coup injuries most commonly affecting the frontotemporal
and occipital cortex. However not all injury occurs at the
time of initial impact. Rather a complex cascade of patho-
physiological effects unfolds over the ensuing hours and
days following injury and results in further tissue damage
[70] (Figure 6). Factors thought important in this secondary
injury cascade include release of excitatory amino acids such
as glutamate, calcium dyshomeostasis, mitochondrial dys-
function and oxidative stress. Increased glucose utilization at
a time of decreased cerebral blood flow also likely exa-
cerbates injury. While these molecular mechanisms are
thought to be operative in moderate to severe TBI, there is
much less in the way of neuropathological or molecular
data on mild TBI and particularly from the mild repetitive
concussions that contribute to CTE. What sets CTE apart
from other injuries is a relentlessly progressive course lead-
ing to a syndrome that continues to progress even in the
absence of further head trauma. Thorough understanding
of this pathological transition in CTE would be facilitated
greatly by an appropriate animal model.
Relevance of existing animal models of TBI to human CTE
Because of its potential clinical importance, animal mod-
eling of TBI has been vigorously pursued and a number
of methods have been developed that can induce focal,
diffuse or mixed brain injury [70]. Most studies of TBI
use rodents, but rabbits, pigs, cats, dogs, and nonhuman
Figure 6 Molecular pathogenesis of TBI and CTE. The upper left panel shows the typical sites of coup/contrecoup injury as occur in blast
as well as other types of closed head injuries. The lower left panel illustrates the most common locations for diffuse axonal injury (pink) and contusions
(blue) following closed head injuries. Reproduced with permission from Taber et al. [80]. The large panel on the right illustrates current concepts of
mechanisms underlying primary and secondary injury mechanisms in TBI. At early times after injury, glutamate release and ionic disturbances (Na+, Ca2+
and K+) disrupt energy metabolism and cause other metabolic disturbances that lead to decreases in cerebral blood flow. Mitochondrial dysfunction
causes increases in reactive oxygen (ROS) and nitrogen species (RNS) that can cause further cellular injury. Tissue damage evokes neuro-inflammatory
changes that emerge later. Injury may be exacerbated by secondary clinical factors including hypoxemia, hypotension, fever and seizures. These
secondary molecular and clinical factors lead to progressive tissue damage. Abbreviations: Ca2+, calcium ions; CPP, cerebral perfusion pressure; Glc,
Glucose; ICP, intracranial pressure; K+, potassium; Na+, sodium; rCBF, regional cerebral blood flow. Reproduced from Marklund et al. [70] with permission.
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of species has practical as well as theoretical implications.
While rodents are less expensive than larger animals, their
lissencephalic brains lack the structure of gyri and sulci
found in humans. The white/grey matter ratio is also less
in rodents compared to human brain; these anatomical
factors may affect the biophysical properties of the brain’s
reaction to mechanical injury. Species such as pigs and
non-human primates offer the advantage of having a brain
more similar to humans, but their cost and in the case of
non-human primates availability limit their wider use for
TBI research.
To model various types of TBI in experimental animals,
several methods have been developed [70]. Among the
more widely used models, controlled cortical impact
(CCI) produces focal contusions with pericontusional
axonal injury while fluid percussion models produce
more diffuse axonal injury. Weight drop methods can
produce a range of injuries depending on the force ap-
plied (mass x distance of the drop), and whether an
open skull or closed skull technique is used. There has
been recently increased interest in models of blast injury,
due primarily to its importance in military head trauma
[71]. Importantly, these models are associated with signifi-
cant deficits in cognitive and motor function. In addition,
anxiety and depression are common features of the post-
concussion syndrome and evidence for impairment in
both domains have been found as sequelae of TBI in
some animal models [72]. There are several recognized
limitations of the animal models. While human TBIrepresents a heterogeneous injury, most animal models
try to replicate more isolated pathological factors [69].
Human TBI is frequently accompanied by hypoxia, hypo-
tension and ischemia, factors that are not prominent in
many animal models [69]. Accordingly, TBI models can
be utilized in combination with additional insults such
as hemorrhagic shock which often accompanies blast
TBI [71]. Another limitation of traditional TBI models
in replicating CTE is that most produce relatively severe
focal or diffuse damage that is more similar to the type of
injury found in moderate to severe rather than mild TBI.
Significant efforts have been made to adapt these models
to produce effects of mild TBI. For example, the CCI
device has been modified to deliver impacts to the intact
mouse skull resulting in a more mild TBI-like outcome
[73]. The weight drop technique has also been used to
produce repetitive mild TBI in the mouse [74,75], and the
lateral fluid percussion model has been modified to deliver
milder injuries in the rat [76]. Additional models have
been developed to mimic mild TBI in combat conditions
including a closed‐head projectile concussive impact in
rats [77], and a model of blast induced repetitive mild TBI
in the rat that has been found to induce chronic behav-
ioral changes [78,79].
Animal models of single‐episode TBI have been valuable
in determining the time course and the extent of cytoskel-
etal derangements which are a key feature of CTE. In
both humans and experimental animals, TBI-induced
axonal damage is associated with extensive accumulation
of multiple proteins [65,81]. Axonal microtubule and
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TBI [82], and they are more pronounced following
moderate injury [83]. In pigs subjected to a rotational
acceleration injury, diffuse axonal damage is characterized
by co-accumulation of tau and Aβ together with NF and
APP throughout the white matter, while in cortical regions
phospho-tau aggregates appear in axonal bulbs as well as
in structures resembling NFT [81]. Similar changes occur
in rodent models of TBI in which alterations in tau and
other microtubule associated proteins can be rapid and
transient [84,85]. For example, in rats subjected to a
mechanical compression injury increased tau phosphoryl-
ation occurs in cortical regions in as little as 10 min
following injury but then is undetectable by 12 hours
[84]. Transient elevations of serum and CSF tau can
also be detected following TBI in rats [86,87]. More
sustained increases in a cleaved form of tau have been
found in the cortex and hippocampus of rats following
a CCI injury [85], and increased phospho-tau has been
observed in cortex of mice 30 days after 5 mild TBI
injuries were delivered utilizing a weight drop device
[75]. A single blast-induced TBI resulted in acute (up to
two weeks) axonal injury in the form of silver impregnated
neuronal processes in rats [88] and increased levels of
phosphorylated tau were detected in NFT like lesions in
mice [58]. In rats, increased levels of tau have been found
in multiple brain regions at 71 days following a blast
injury [89]. Thus acute to subacute changes in tau are
common across a spectrum of experimental TBI models.
However, few studies have yet revealed whether a sub-
sequent chronic neurodegenerative changes are induced.
Indeed the only study to our knowledge that has addressed
this issue is the study by Hoshino et al. [90] who studied
the chronic effects of fluid percussion injury in rats.
They reported a progressive loss of cortical neurons
over a six-month period accompanied by appearance of
increasing numbers of phospho-tau immunoreactive neu-
rons [90]. As noted above, rodent models of TBI are
widely used because of their accessibility and relatively
low cost. However, in addition to the anatomic differences
between rodent and human brain, rodent models for CTE
are potentially limited by the fact that mice and rats
do not readily develop human like neurofibrillary
pathology, a key histopathological feature of CTE.
Rodents and humans differ in life spans, and species
differences in tau also contribute to the difficulty of
inducing NFT like lesions in rodents. The lack of
human-like NFT pathology in rats and wild type mice
has in particular been a limiting factor in the development
of CTE models and has led to attempts to create more
human like tauopathy models by introducing human tau
transgenes into mice.
The non-traumatic neurodegenerative diseases that most
closely resemble CTE pathologically are some forms offrontotemporal dementia (FTD). While most FTD cases
can occur without evidence of family history, in some
families the disease is inherited and caused by mutations
in the tau gene on chromosome 17 [91]. Mice expressing
either human wild type or FTD-‐mutant tau develop a
neurodegenerative disease spontaneously and accumulate
NFT‐like lesions with aging [92]. These lines have been
used to investigate tauopathy‐related dementias and offer
potentially relevant models for CTE [92]. However to date
only limited use has been made of these mice to study
TBI. One study [93] examined the effects of mild repeti-
tive TBI using a CCI injury in transgenic mice expressing
the shortest human tau isoform. Transgenic and non-
transgenic mice were subjected to a total of 16 mild TBI
injuries over a period of 4 weeks and animals were
examined histopathologically at 9 months after injury.
Despite this aggressive injury protocol there was no
general effect on histopathology or behavior of the tau
transgene other than in one of the 18 transgenic mice that
showed behavioral deficits and developed extensive
telencephalic NFT like lesions and cerebral atrophy. In
contrast, increases in total and phospho-tau immuno-
reactivity have been seen following a more severe CCI
injury in JPNL mice which express the four repeat
form of human tau containing the P301L mutation
associated with FTD [94]. In another study, mice that
expressed the 6 isoforms of human tau and lacked
murine tau were subjected to a single or repetitive mild
TBI using an electromagnetically controlled impactor;
three weeks later, phospho‐tau immunoreactivity, neur-
onal injury, and glial reaction were more pronounced in
the group with repetitive mild TBI [95].
As discussed above, CTE is a heterogeneous disease with
inconsistent pathology including not only tau but also Aβ
lesions. Accordingly, several studies have investigated the
effects of TBI in 3xTg-AD mice [94,96,97]. These mice also
express the P301L mutation in tau associated with FTD
but in combination with APP and presenilin mutations
associated with familial Alzheimer’s disease. With aging
these mice develop increased Aβ40 and Aβ42 levels,
accumulate intraneuronal Aβ and exhibit amyloid plaques
and NFT like lesions, thus exhibiting a more complete
spectrum of AD like pathology when compared to other
transgenic mouse models. Controlled cortical impact
injury in 3xTg-AD mice accelerated the development of
tau abnormalities [96] with increased phospho‐tau immu-
noreactivity seen histologically in the days following injury
[96]. Tau changes persisted for at least 7 days after injury
and were associated with intra-axonal accumulation of
several kinases that phosphorylate tau [96]. In agreement
with previous reports in other transgenic mouse models
[98-100], the CCI injury in 3xTg-AD mice also resulted
in intra-axonal Aβ accumulation [96]. However, in this
model combining tauopathy and amyloidosis, the anatomic
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distinct [96], and treatment with a γ‐secretase inhibitor
blocked posttraumatic Aβ accumulation but had no effect
on tau pathology suggesting that once initiated these two
pathologies may take independent courses of progression
[96]. In contrast, reports from Loane et al. indicate that
Aβ-reducing agents prevented TBI-induced neurodegen-
eration [101,102].
Better animal models of CTE are an urgent need given
that to date no injury in animals has replicated the full
spectrum of pathological findings in human CTE. Acute
to subacute changes in tau are common across a range
of experimental TBI models suggesting that injured
animals can manifest at least some initial cytoskeletal
changes observed in brains of humans with CTE. How-
ever most studies have focused on acute effects of TBI
and greater attention should be directed to determining
whether a chronic neurodegenerative condition can be
induced after TBI in animals. As mild TBI and concus-
sions draw increasing attention as the most common type
of civilian and military TBI, future studies of repetitive
concussions in both rodent and non-rodent species will
be needed to determine the optimal model.Neuroimaging of CTE
Identification of specific imaging biomarkers for CTE has
been challenged by the lack of correlation between any
available neuroimaging studies and post-mortem tissue
assessments demonstrating histopathologic hallmarks of
CTE. To date, no systemic in vivo biological markers have
been identified that reveal the presence of CTE. Given
that most case reports of CTE involve individuals with a
history of repetitive sports-related trauma, the neuroimag-
ing portion of this review will focus upon abnormalities
present in athletes with a history of concussion.
Common structural abnormalities often reported in the
brain of professional boxers include cavum septum pel-
lucidum (often with fenestrations), ventricular and sulcal
enlargement, and cortical and cerebellar atrophy. Although
CSP is often reported in studies of boxers and is postulated
to be a sign of DP/CTE [43], and a marker of brain atrophy
[44,103,104], its relatively high incidence in the normal
adult population precludes its presence as a diagnostic
specific to boxing [105]. Despite the lack of specific
in vivo findings in CTE, studies using both traditional
and newer imaging methods have advanced our under-
standing of the consequences of repetitive head trauma.
Newer imaging modalities and the use or development
of advanced analytical methods (e.g., ref [106]) have
revealed brain abnormalities in repetitive head trauma
where more traditional methods found none, suggesting
that comprehensive evaluation of CTE should include
neuroimaging as part of an overall clinical assessment.Structural Imaging
The major traditional structural imaging techniques used
to evaluate brain function in boxers, and more recently
in football players, are computed tomography (CT) and
magnetic resonance imaging (MRI). In acute settings,
these standard, structural imaging techniques have clinical
utility in ruling out other acquired brain disorders such
as tumor or stroke and have been utilized to rule out
potentially fatal consequences of acute TBI such as hemor-
rhagic contusion, subdural and epidural hematomas, and
subarachnoid hemorrhage. However, structural (or func-
tional for that matter) imaging findings alone are not
sufficient to diagnose CTE or determine who might even-
tually develop CTE. In addition, some of the structural
imaging changes identified in CTE are similar to those
seen in AD [107], and there may be similarities as well
with normal aging. Early studies demonstrated that CT
might not be as effective as MRI in identifying injury in
the acute phase [108]. In non-acute settings, high-field
MRI may be the preferred modality in the evaluation of
TBI due to its improved tissue clarity and contrast of
pathology, and because it eliminates the risk of ionizing
radiation associated with CT [103,107,109]. These features
of MRI make it a valuable diagnostic tool for determining
the extent of chronic TBI [107].
In view of the improved tissue contrast and additional
biologically relevant information afforded by MRI, early
studies began to investigate whether MRI was superior to
CT as an imaging modality in boxers. A study conducted
in 1990 did not demonstrate MRI superiority to CT in 47
retired amateur boxers as compared to two age-matched
control groups: soccer and track and field athletes [110].
However, another study published that same year found
that some abnormalities detected by MRI were not shown
by CT [103]. There were several limitations in these early
studies, including comparison of professional boxers to
amateur boxers, who may not show neurologic damage
because of their limited number of exposures, and incom-
plete information in professional boxers in terms of
number of years spent boxing or the number of bouts
fought. In addition, most studies were cross-sectional,
thus it cannot be determined from these studies whether
the abnormalities were present before or the result of,
boxing [105]. It should be noted that both MRI and CT
have seen dramatic technological improvements over the
past two decades.
A recent review of the MRI literature [107] used a
systematic checklist approach to assess 100 unselected
consecutive 1.5 and 3.0 Tesla MRI examinations of pro-
fessional boxers to determine the extent of identifiable
TBI findings. Results indicated that 76% of boxers had
at least one finding associated with TBI: 59% had hip-
pocampal atrophy, 43% CSP, 32% dilated perivascular
spaces, 29% diffuse axonal injury, 24% cerebral atrophy,
Gandy et al. Molecular Neurodegeneration 2014, 9:37 Page 13 of 21
http://www.molecularneurodegeneration.com/content/9/1/3719% increased lateral ventricular size, 14% pituitary gland
atrophy, 5% arachnoid cysts, and 2% had contusions [107]
(Figures 7 and 8). Statistical relationships were found
between number of bouts and lateral ventricular size, and
years of fighting correlated with dilated perivascular
spaces and diffuse axonal injury. An earlier systematic
review of the literature from 1985 to 2000 [111] on
concussion in a variety of contact sports, found that
male boxers had the highest frequency of concussion at
the recreational level [111]. While these reviews indi-
cate significant brain abnormalities in boxers exposed
to frequent concussive and subconcussive blows to the
head, prospective studies will be needed to determine
whether the underlying process is degenerative and
progressive in nature and related to and consistent with
CTE clinical outcomes.
Diffusion tensor imaging
Newer imaging techniques such as diffusion tensor im-
aging (DTI) (Figure 9) are more sensitive for identifying
the presence of axonal injury that occur due to the
shearing forces of TBI. DTI is a relatively new technique
and provides information reflecting the integrity of white
matter fiber tracts.
Quantitative values used for spatially mapping DTI
include apparent diffusion coefficient (typically mean
diffusivity, MD), which measures the magnitude of the
diffusion of water molecules, and fractional anisotropy
(FA) or relative anisotropy (RA), which measure the
directional preference of water molecules throughout
brain fibers. White matter tracts normally constrain the
isotropic diffusion of water. An FA value approaching
1.0 reflects maximal anisotropic diffusion, and values
approaching zero indicate compromised white matter
integrity. In addition to FA and RA, axial diffusivity andFigure 7 Diffuse axonal injury on MRI. (Panels A–F) Typical diffuse axon
abnormal increased signal intensity on FLAIR and T2-weighted sequenc
at the gray matter = white matter interface or within or adjacent to the
Reproduced Ïrom Orrison et al. [107] with permission.radial diffusivity describing magnitude of diffusion longi-
tudinal and transverse to the dominant direction of white
matter tracts may also be derived from the calculated
diffusion tensor. DTI values are affected when there are
changes to the microstructure of brain tissue. Disruption
of axonal integrity due to shearing forces associated with
head trauma results in a general reduction of FA values
as the normal barrier to isotropic diffusion is altered.
This type of information is not available from routine
MRI; thus, white matter abnormalities that may be
present due to repetitive TBI often go undetected with
routine imaging.
Chappell et al. [113] used a voxel-based analysis of DTI
data to examine the ADC and FA in professional boxers
and found previously unreported abnormalities that were
assumed to reflect cumulative brain injury resulting
from non-severe, repetitive head trauma [113]. Regions
were found to have increased ADC, decreased FA, and
decreased ADC in gray matter in the boxer group com-
pared to a group of controls with no neurological history.
The regions affected included lower splenium and cortical
regions laterally and dorsolaterally in the frontal and
posterior lobes. The authors concluded that their findings
represented evidence that sustained boxing activity causes
structural abnormalities in the brain.
Similarly, an earlier study by Zhang and colleagues
[114] using quantitative diffusion weighted imaging (DWI)
found increases in the whole brain diffusion constant in
professional boxers as compared to age-matched, non-
boxing control subjects. The increased diffusion values
were observed despite negative or nonspecific results on
routine MR imaging, indicating that this imaging modality
may show early pathologic changes in the cellular and
microvascular structure of the brain in boxers. Zhang
et al. [114] postulated that given the similar findings inal injury, indicated by arrow. DAI was defined as focal areas of
es, measuring up to 5 mm in maximum diameter, and located
corpus callosum. In the Orrison et al. sample, 29% had DAI.
Figure 8 Cavum septum pellucidum (CSP) on MRI. (A) Mild
(B) Moderate. No severe CSP was observed. Orrison et al. [107]
examined one hundred consecutive unselected MRI scans that were
performed on professional unarmed combatants (boxers and mixed
martial arts fighters) in two outpatient imaging settings. Seventy-five
were imaged on a 1.5-Tesla (T) MRI system and 25 were imaged on
a 3.0-T high field MRI system. CSP was defined as the presence of a
fluid filled space separating laminae of the septum pellucidum. CSP
was graded as mild, moderate, or severe. CSP was found in 42% of
subjects, due in part due to the improved resolution of the higher
field strength MRI systems used.
Figure 9 BOLD imaging was acquired from college football
players while performing a bimanual sequencing task. The
“concussed” group consisted of four individuals who were within
one week of sustaining a concussion. The “control” group included
the additional four players who did not receive a concussion, with
imaging acquired post‐season. Regions of significantly increased
activity during performing of the bimanual sequencing task are seen
within the brains of those individuals who sustained a concussion as
compared with controls. Images and data are reproduced from
Jantzen et al. [112] with permission.
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whole brain diffusion coefficient represents preclinical
signs of cognitive decline [114]. A later study by Zhang
et al. [115] using DTI in a sample of 49 professional
boxers and 19 healthy controls focused on the corpus
callosum and the internal capsule. In that study, 42
boxers (86%) had a normal routine, clinical MRI and 7had nonspecific white matter disease. In the boxer group,
the whole brain diffusion constant was increased and FA
was decreased significantly in the CC and posterior limb
of IC, which the authors postulate may represent preclin-
ical signs of subtle brain injury in professional boxers.
Importantly, the increases in diffusion were found without
brain abnormalities revealed on standard MR images,
suggesting that diffusion tensor imaging is an important
tool in the monitoring of brain function in professional
boxers [113-115] and may be particularly useful in the
multivariate diagnostic evaluation of individuals with
CTE (Figure 10).
Functional magnetic resonance imaging (fMRI)
fMRI involves acquisition of a blood oxygen level depend-
ent (BOLD) sequence during performance of a specific
task (Figure 11). The BOLD sequence is sensitive to
Figure 10 Diffusion tensor imaging (DTI) of TBI. Diffusion weighted volumes in 64 directions were collected from 22 patients with TBI
(18 moderate/severe and 4 mild based upon Mayo classification system for TBI severity) and from 21 age-matched controls. Processing for DTI
was performed and anatomic regions-of-interest were identified in controls for performing probabilistic tractography to study thalamo-cortical connections.
Templates were generated that included white matter tracts isolated from probabilistic tractography. All brains were transformed into standard space and
templates were applied to TBI patients and healthy controls to explore differences in white matter integrity between groups. Patients with a small
(A) and large (B) number of abnormal voxels are shown. Histograms of MD values (C) from the patient shown in frame A (blue), frame B
(red), as compared with a mean atlas (D) are shown. Images and data are reproduced from Squarcina et al. [116] with permission.
Figure 11 Sparse canonical correlation analysis (SCCA) of T1-weighted MP‐RAGE and 30-direction diffusion tensor images (DTI) datasets
are used to quantify traumatically induced disruption of WM and cortical networks. The cohort includes 17 controls and 16 patients with TBI
(age and gender matched). Each patient had a history of non‐penetrating TBI of at least moderate severity. White matter integrity is assessed by DTI
and fractional anisotropy (FA) maps are generated. Separately, probabilistic segmentation of the T1‐weighted imaging is performed to assess gray
matter integrity. Variation in brain shape across subjects is normalized by diffeomorphically mapping these data into a population-specific template
space. Image processing steps rely on the Camino and ANTs (Advanced Normalization Tools) neuroimage analysis open source toolkits. SCCA
demonstrates significant differences between the control and patient groups in both the FA (p < 0.002) and gray matter (p < 0.01) that
are widespread but largely focus on thalamocortical networks related to the limbic system. Using SCCAidentified regions, a strong correlation is
identified between degree of injury in WM and GM within the patient group. Figure courtesy of James R. Stone.
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strate regional variations in blood oxygenation. It is believed
these changes in blood oxygenation reflect variations in
neuronal activity. However, this point is a subject of contro-
versy given the potential for the neurovascular apparatus to
be altered in states of disease.
Distinct regional differences in BOLD signal have been
reported in multiple studies of concussed athletes vs.
controls. Chen et al. [117] utilized fMRI with a working
memory task to study 16 athletes (13 hockey players,
2 wrestlers, one snowboarder), most of whom had a history
of > 5 career concussions. An interval of between 1 and
14 months had passed between the scan and time of last
concussion. Although no differences in task performance
were seen between groups, significantly different regional
patterns of activation were seen within the mid-
dorsolateral prefrontal cortex (MDPC) in the concussed
athletes as compared to controls. In a separate study,
Chen et al. [118] utilized an fMRI working memory task
to demonstrate abnormal activation patterns in the
MDPC in 9 concussed athletes as compared to controls.
Of note, no significant differences were seen with routine
structural imaging or behavioral outcomes between groups.
Lovell et al. [119] employed an N-back working memory
task to evaluate 28 athletes within a mean of 6.6 days after
sustaining a concussion. A components analysis identified
three distinct networks that were activated in both con-
cussed athletes and controls during participation in the
N-back task. One of these networks involving Brodman’s
area 6 demonstrated increased levels of activity in con-
cussed athletes compared with controls. Of note, the degree
of increased activation in Brodmann’s area 6 in the con-
cussed athletes correlated significantly with prolonged
recovery time and delayed return to play.
Positron emission tomography (PET)
PET imaging allows for characterization of the uptake
and spatial localization of radiotracers injected intraven-
ously (IV). This imaging modality allows for the sensitive
detection of small molar concentrations of radiotracers
given its sensitivity for detecting the high-energy photons
(512 keV) produced by radioactive decay through pair
production. PET imaging in sports related TBI is
currently limited and has generally been confined to
use of 18fluoro-deoxyglucose (18FDG), a glucose analog
that reflects metabolism. In brain, where glucose is the
sole energy source, 18FDG is an excellent tracer for this
purpose. Provenzano et al. [120] employed 18FDG PET
to study 19 boxers, aged 20 to 38 yrs, and compared them
to 7 age-equivalent controls. The boxers had participated
in an average of 17.3 matches, had performed poorly in a
match or had been knocked out, and were referred for
assessment because of clinical signs of neurological impair-
ment. The PET scans were acquired as an element of theclinical work-up. Retrospective evaluation of these scans
was performed. Specific regions of hypometabolism were
seen in the boxers’ brains as compared to those of the
controls, including the posterior cingulate cortex, parieto-
occipital cortex, frontal lobes, and cerebellum.
In addition to assessing regional metabolism, PET
can be used to detect the presence of specific molecules or
abnormal cellular processes (molecular imaging). Aβ·depo-
sition is an inconsistent feature in CTE. Diffuse plaques are
found in about half (47%) of neuropathologically verified
CTE cases [21], a figure that represents a greater frequency
than that observed acutely after severe TBI (~30%) [51].
PET imaging using Aβ probes are being currently used in
large scale studies of AD. The use of amyloid imaging
in suspected CTE has not been established but will be
of interest given the similarity between AD and CTE
phenotypes and may be useful in determining whether the
presence of amyloid post TBI can help predict outcome.
This will be of particular interest if the presence of amyl-
oid is associated with worse outcomes, since interventions
that reduce the trajectory of brain amyloid accumulation
have already been identified in studies of AD.
The original Corsellis series identified diffuse amyloid in
50% of the cases of DP. As mentioned above, DeKosky
reported acute amyloidosis within hours or days even in
young patients [51]. The natural history of these deposits
remains to be established, and this is an important ques-
tion that can now be addressed with amyloid imaging.
Menon has recently reported just such a study, and his
conclusion is that the initial burst of amyloidosis is rapidly
cleared [121]. One wonders, however, whether clearance
might become less efficient as repeated TBI occurs, and
longer term studies of such a possibility are underway in
our center. In another study, about half of subjects in
the chronic phase of recovery from a severe TBI showed
positive amyloid scans [122].
Of particular relevance to CTE, PET imaging ligands
are now in development for detection of abnormally
phosphorylated tau associated with neurofibrillary tangles
(Figure 5). Zhang et al. [19] recently reported develop-
ment of an 18 F labeled compound ([18 F] T807) which
demonstrated high affinity and selectivity for tau in
competitive assays designed to assess tau binding in
post-mortem human brain slices derived from individ-
uals with AD. This study also reported high uptake and
washout in rodent brains, suggesting adequate blood brain
barrier penetration. Given the presence of abnormally
phosphorylated tau tangles in CTE, there is great interest
in exploring the utility of this probe as a potential in vivo
marker for CTE. Successful developmdent of a molecular
imaging ligand for neurofibrillary tangles would open the
door for epidemiological studies to assess to the true
prevalence of this disease, correlative studies to determine
other potential imaging diagnostics for CTE, and as a
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or mitigation strategies for the treatment or prevention of
CTE. Recent reports indicate that [18F] T807 has been
successfully employed for the detection of CTE tauopathy
in vitro and in vivo [123-125] (Figure 12).
In summary, neuroimaging in CTE holds promise in
serving as an in vivo biomarker and should be used in
adjunct with a comprehensive history and thorough
clinical diagnostic evaluation in life. Prospective, longi-
tudinal neuroimaging studies are needed to help define
the clinical and biological markers associated with, andFigure 12 [18F]-T807 PET imaging from a 71-year-old retired
NFL player. [18F]-T807 signals (arrows) originate from the globus
pallidus (GP), substantia nigra (SN), and hippocampus. Images depict
axial (A) sagittal (B) and coronal (C and D) orientation of the brain.
A, anterior; P, posterior; L, left; R, right; H, head. Images and data are
reproduced from Mitsis et al. [123] with permission.specific to, CTE. Body fluid markers may eventually
complement neuroimaging markers, especially in medical
centers without access to PET. These body fluid markers
have recently been reviewed in detail elsewhere [126].
Conclusions
The association of CTE with certain sports and with
battlefield blast exposure provides a mandate for the
construction of accurate databases and epidemiological
studies. Securing valid incidence, prevalence, and relative
risk data are essential. Current academic papers continue
to meet with criticism that the risk is being overstated
[127,128]. While awaiting accurate data upon which to
estimate relative risk, informed consent should be devel-
oped and offered to those contemplating exposure to
repetitive TBI. While the administrative organizations
of high impact sports and the military are the obvious
organizations to begin informing potential athletes and
recruits about the possible risk of CTE, another significant
challenge will be the development of informed consent
procedures for those overseeing the exposure of children
and adolescents [27]. Finding the right balance of estab-
lished fact and informed opinion will be a challenge, so as
not to create unnecessary concern. Extension of genetic
epidemiology studies to the pediatric and adolescent
population will also be a challenge, albeit a worthy one
[27]. The acquisition of definitive data about what genetic
factors identified in adolescents are predictive of the
eventual personal risk of CTE will require decades of
study but are essential.
In parallel, application of validated laboratory models
and execution of human clinical trials in the TBI/CTE
area should be accelerated. Adaptation of repetitive TBI
systems to the mouse holds promise for elucidating the
molecular pathogenesis of CTE. The role of APOE geno-
type should be given high priority in both the animal and
the human clinical studies [25,27]. Compounds emerging
from drug discovery efforts in academic and pharma-
ceutical neurodegenerative disease programs should be
considered for assessment in TBI [100]. Emerging data
from the AD literature indicating the key role of immune-
inflammatory processes may illuminate CTE as well. New
data implicate IL-1β in facilitating the development of
tauopathy while reducing amyloidosis [68]. Tau oligom-
erization [129] may also contribute to the pathogenesis
of CTE and may emerge acutely or after a delay [90].
Taken together with the Aβ independence of progressive
tauopathy as reported by Brody [96], the hypothesis that
tauopathy and amyloidosis can be dissociated in TBI is
supported. The strong association of PTSD with TBI
should also be evaluated and clarified [79].
The challenge of accelerating molecular neuropathology
research in an era of dwindling resources is a major
concern. Recent alliances between the NFL and the NIH,
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Department of Defense and the NIH Alzheimer’s Disease
Neuroimaging Initiative provide some optimism that
all the stakeholders are becoming engaged. Permanent
commitment and substantial resources from these stake-
holders will be required to offset the general reductions
in federal support (including NIH and the Department of
Defense) due to policies resulting in the recent sequestra-
tion of federal funds. In the absence of reliable prevalence
data, the calculation of the potential healthcare savings by
reduction of TBI exposure is not possible. The total cost
of TBI exposure, of course, must take into account what
may be enormous payouts from potential class action
litigation verdicts. In addition to significant fiscal savings,
the support of translational and clinical research programs
in TBI/CTE and of development of policies that mitigate
some or all of the attributable dementia risk represented
by TBI/CTE is obviously justifiable on compassionate
grounds. TBI, whether deliberate or unavoidable exposures,
represents a source of pain and suffering that could be
eliminated or at least greatly reduced with the pooled com-
mitment and resources of the medical, sports, and military
sectors. The high visibility of CTE in the media in the early
21st century makes this an opportune moment to apply the
information reviewed herein so as to make important ad-
vances in elucidation of pathogenesis and in drug discovery.
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